Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases.

Protara’s lead cell-based therapy, TARA-002, is being tested for treatment of non-muscle invasive bladder cancer (NMIBC) in an ongoing Phase 2 trial. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.